The Medicare GLP-1 Bridge: How to Check If You're Eligible and Apply
The new CMS demonstration program (launched July 1, 2026) creates the first Medicare pathway for GLP-1 obesity treatment. Eligibility checklist, step-by-step application, and what to do if you don't qualify.
The Medicare GLP-1 Bridge is a CMS demonstration program that launched July 1, 2026 — the first Medicare pathway specifically covering GLP-1 medications for obesity treatment. If you're on Medicare and have been waiting for coverage, here's exactly how to check eligibility and get started.
What the Bridge covers
The demonstration covers brand-name semaglutide (Wegovy) and tirzepatide (Zepbound) at FDA-approved obesity doses through Medicare Part D. It does not cover compounded GLP-1 medications regardless of pharmacy type. It runs through December 31, 2027.
Eligibility checklist
You qualify if all of these apply
- Enrolled in Medicare Part D (any plan)
- BMI ≥30 kg/m², OR BMI ≥27 with at least one qualifying comorbidity
- Qualifying comorbidities (if BMI 27-30): T2D, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease
- Prescription from a Medicare-participating provider
- Prior authorization approved by your Part D plan
Every Part D plan administering the Bridge must cover the medications, but each plan sets its own prior authorization process. You'll need documentation from your prescriber: your BMI, the obesity diagnosis code (E66.x), and any qualifying comorbidities. Your prescriber can submit the PA on your behalf — confirm they're familiar with the Bridge program before your visit.
How to apply, step by step
- Confirm your Part D plan participates. Call your plan's member services or check the CMS GLP-1 Bridge plan finder at medicare.gov.
- Get your BMI documented. You need a measured BMI on file from a licensed provider — self-reported doesn't count for PA purposes.
- Get a prescription. Telehealth prescribers who participate in Medicare can prescribe through the Bridge — you don't need an in-person visit.
- Submit prior authorization. Your prescriber handles this, but confirm they know the Bridge program code and your specific plan's PA form.
- Fill at a covered pharmacy. Compounding pharmacies are excluded — use your plan's standard pharmacy network.
What if you don't qualify for the Bridge?
If your BMI or comorbidity profile doesn't meet Bridge criteria, or if your plan's PA is denied, cash-pay telehealth remains the practical alternative. Compounded semaglutide and tirzepatide through licensed telehealth platforms run $150–350/month — far below brand-name list prices.
Verified telehealth providers
Medicare-compatible telehealth visits. Licensed providers who can submit Medicare PA for the GLP-1 Bridge.
Paid link Get started →50-state GLP-1 program. Can bridge Medicare and cash-pay depending on eligibility.
Paid link Get started →